Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

Abstract

Introduction:In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and patient-reported outcome measures (PROMs) among patients with moderate-tosevere plaque psoriasis. However, limited information is available regarding the real-world effectiveness of guselkumab among patients with psoriasis of mild, moderate, and severe Investigator's Global Assessment (IGA) severities living in the USA and Canada. Methods: Patients participating in the CorEvitas Psoriasis Registry between

Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries

“…In particular, Guselkumab, in which the mechanism of action occurs through selective inhibition of IL-23 via binding to its p19 subunit, demonstrated greater efficacy and durability of response in the treatment of plaque-type psoriasis compared with a placebo [90]. Therefore, emerging studies have observed a good therapeutic effect after treatment with Guselkumab of patients affected by psoriasis vulgaris complicated by SSc, improving each symptom of SSc, such as immune abnormalities, fibrosis, and vasculopathy [91]. Unfortunately, the administration of anti-IL-23 agents has not had positive effects in all patients, and they can cause undesirable immunological and non-immunological adverse events.…”

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

“…There has been an evolution of the inclusion criteria and primary endpoints in the pivotal trials, 29 but it was only recently that studies began to include patients with mild‐to‐moderate psoriasis. For example, patients with baseline Investigator's Global Assessment (IGA) score ≥2 were included in a real‐world registry evaluation the effectiveness of guselkumab 30 . One oral target agent, apremilast, has successfully expanded its indication into psoriasis patients with all degrees of severity 31,32 .…”

“…were included in a real-world registry evaluation the effectiveness of guselkumab. 30 One oral target agent, apremilast, has successfully expanded its indication into psoriasis patients with all degrees of severity. 31,32 Nonetheless, studies specifically targeting patients with mild-to-moderate diseases activity remained limited except for psoriasis localized on specific areas such as scalp, 33 palmoplantar areas 34 and genitalia.…”